Concepts (85)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 5 | 2025 | 1742 | 1.330 |
Why?
|
| Gulf War | 1 | 2025 | 10 | 0.910 |
Why?
|
| Persian Gulf Syndrome | 1 | 2025 | 16 | 0.900 |
Why?
|
| Pharmacogenomic Testing | 1 | 2024 | 44 | 0.880 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2024 | 33 | 0.880 |
Why?
|
| Suicidal Ideation | 1 | 2025 | 249 | 0.730 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 457 | 0.630 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2022 | 650 | 0.470 |
Why?
|
| Anti-HIV Agents | 3 | 2023 | 345 | 0.450 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2023 | 54 | 0.430 |
Why?
|
| Substance-Related Disorders | 2 | 2024 | 486 | 0.290 |
Why?
|
| HIV Infections | 3 | 2023 | 1953 | 0.250 |
Why?
|
| Tramadol | 1 | 2024 | 7 | 0.220 |
Why?
|
| Codeine | 1 | 2024 | 21 | 0.220 |
Why?
|
| Epigenomics | 1 | 2025 | 174 | 0.210 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2024 | 42 | 0.210 |
Why?
|
| Pharmacogenetics | 1 | 2024 | 197 | 0.200 |
Why?
|
| Depression | 2 | 2022 | 1294 | 0.200 |
Why?
|
| Afghanistan | 1 | 2022 | 16 | 0.200 |
Why?
|
| Iraq | 1 | 2022 | 11 | 0.200 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 227 | 0.190 |
Why?
|
| United States | 4 | 2025 | 11379 | 0.190 |
Why?
|
| Pain | 1 | 2024 | 428 | 0.180 |
Why?
|
| Schizophrenia | 1 | 2024 | 320 | 0.170 |
Why?
|
| Patient Navigation | 1 | 2021 | 23 | 0.170 |
Why?
|
| Counselors | 1 | 2021 | 23 | 0.170 |
Why?
|
| Text Messaging | 1 | 2021 | 39 | 0.170 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 692 | 0.170 |
Why?
|
| Police | 1 | 2020 | 14 | 0.160 |
Why?
|
| Liraglutide | 1 | 2020 | 13 | 0.160 |
Why?
|
| Appetite Depressants | 1 | 2020 | 23 | 0.160 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2020 | 46 | 0.160 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 3932 | 0.160 |
Why?
|
| GABAergic Neurons | 1 | 2020 | 56 | 0.160 |
Why?
|
| Health Personnel | 1 | 2024 | 535 | 0.150 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 2019 | 13 | 0.150 |
Why?
|
| Nurses | 1 | 2020 | 78 | 0.150 |
Why?
|
| Calcitonin | 1 | 2019 | 31 | 0.150 |
Why?
|
| Genome-Wide Association Study | 2 | 2024 | 1728 | 0.150 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2019 | 74 | 0.150 |
Why?
|
| Genotype | 1 | 2024 | 2598 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 753 | 0.140 |
Why?
|
| Middle Aged | 3 | 2025 | 27807 | 0.120 |
Why?
|
| Humans | 10 | 2025 | 127268 | 0.120 |
Why?
|
| Biomarkers | 1 | 2025 | 3234 | 0.120 |
Why?
|
| Adult | 4 | 2025 | 30530 | 0.120 |
Why?
|
| Anxiety Disorders | 1 | 2021 | 696 | 0.120 |
Why?
|
| Weight Loss | 1 | 2019 | 503 | 0.120 |
Why?
|
| Anxiety | 1 | 2021 | 964 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 886 | 0.110 |
Why?
|
| Male | 6 | 2025 | 62778 | 0.100 |
Why?
|
| Female | 6 | 2025 | 68592 | 0.100 |
Why?
|
| Young Adult | 1 | 2025 | 9694 | 0.080 |
Why?
|
| Risk Factors | 1 | 2022 | 10603 | 0.070 |
Why?
|
| Obesity | 1 | 2019 | 2338 | 0.070 |
Why?
|
| Eating | 2 | 2020 | 359 | 0.070 |
Why?
|
| Rats | 2 | 2020 | 3395 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2025 | 260 | 0.050 |
Why?
|
| Intention | 1 | 2023 | 100 | 0.050 |
Why?
|
| Perception | 1 | 2023 | 228 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2025 | 659 | 0.040 |
Why?
|
| Philadelphia | 1 | 2021 | 27 | 0.040 |
Why?
|
| Counseling | 1 | 2023 | 234 | 0.040 |
Why?
|
| New York City | 1 | 2021 | 63 | 0.040 |
Why?
|
| Solitary Nucleus | 1 | 2020 | 4 | 0.040 |
Why?
|
| Program Development | 1 | 2021 | 181 | 0.040 |
Why?
|
| Health Facilities | 1 | 2020 | 67 | 0.040 |
Why?
|
| Violence | 1 | 2020 | 128 | 0.040 |
Why?
|
| Receptors, Glucagon | 1 | 2019 | 32 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2021 | 424 | 0.040 |
Why?
|
| Anti-Obesity Agents | 1 | 2019 | 44 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2021 | 438 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 1399 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 750 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 785 | 0.030 |
Why?
|
| Diet, High-Fat | 1 | 2019 | 239 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2020 | 1127 | 0.030 |
Why?
|
| Energy Intake | 1 | 2019 | 495 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 971 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2019 | 1082 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 4975 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 761 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 669 | 0.030 |
Why?
|
| Animals | 2 | 2020 | 33187 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 20427 | 0.010 |
Why?
|